in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Ipsen expects Increlex supply interruption due to issues at Lonza Hopkinton site
8:43 AM MDT | April 29, 2013 | Deepti Ramesh
Pharmaceutical company Ipsen (Paris) says that it expects a supply interruption for its product Increlex, a treatment for growth failure in children, as a result of the manufacturing issues at Lonza’s Hopkinton, MA, site that supplies the active ingredient for Increlex. The US in 2011 to Lonza’s pharmaceutical and active pharmaceutical ingredient manufacturing facility at Hopkinton for deviating from cGMP. Lonza is working with the FDA to address these issues and Ipsen is addressing management of the shortage to reduce its impact on the patients and...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee